Erratum: Managing bone metastases and reducing skeletal related events in prostate cancer (Nature Reviews Clinical Oncology (2014) 11 (335-345) DOI:10.1038/nrclinonc.2014.70);Managing bone metastases and reducing skeletal related events in prostate cancer

Nature Reviews Clinical Oncology

Volumn 11, Issue 6, 2014, Pages 335-345

  Gartrell, Benjamin A ^a   Saad, Fred ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CABOZANTINIB; CLODRONIC ACID; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; IBANDRONIC ACID; NERIDRONIC ACID; PAMIDRONIC ACID; PLACEBO; PREDNISONE; RADIOPHARMACEUTICAL AGENT; RADIUM 223; RALOXIFENE; RISEDRONIC ACID; SAMARIUM 153; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM 89; TOREMIFENE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; BONE DISEASE; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL ACTIVITY; DISEASE ASSOCIATION; DRUG EFFICACY; FRACTURE; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; MORBIDITY; NEPHROTOXICITY; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; OVERALL SURVIVAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SKELETAL RELATED EVENT;

BONE NEOPLASMS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84901983312     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.201     Document Type: Erratum

References (109)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
2. Jacobs, S. C. Spread of prostatic cancer to bone. Urology 21, 337-344 (1983).
3. Scher, H. I., Morris, M. J., Kelly, W. K., Schwartz, L. H. & Heller, G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin. Cancer Res. 11, 5223-5232 (2005).
4. Coleman, R. E. Skeletal complications of malignancy. Cancer 80, 1588-1594 (1997).
5. DePuy, V. et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15, 869-876 (2007).
6. Oefelein, M. G., Ricchiuti, V., Conrad, W. & Resnick, M. I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J. Urol. 168, 1005-1007 (2002).
7. Alibhai, S. M. et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J. Urol. 184, 918-923 (2010).
8. Manolagas, S. C. & Jilka, R. L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332, 305-311 (1995).
9. Lacey, D. L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
10. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
11. Kong, Y. Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
12. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
13. Li, J. et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl Acad. Sci. USA 97, 1566-1571 (2000).
14. Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
15. Yasuda, H. et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337 (1998).
16. Keller, E. T. & Brown, J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J. Cell. Biochem. 91, 718-729 (2004).
17. Guise, T. A. Molecular mechanisms of osteolytic bone metastases. Cancer 88, 2892-2898 (2000).
18. Saad, F. Bone-directed treatments for prostate cancer. Hematol. Oncol. Clin. North Am. 20, 947-963 (2006).
19. Snedecor, S. J., Carter, J. A., Kaura, S. & Botteman, M. F. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis. J. Med. Econ. 16, 19-29 (2013).
20. Berruti, A. et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br. J. Cancer 93, 633-638 (2005).
21. Tchekmedyian, N. S., Chen, Y. M. & Saad, F. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest. 28, 849-855 (2010).
22. Saad, F. et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96, 879-882 (2004).
23. Saad, F., Segal, S. & Eastham, J. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. Eur. Urol. 65, 146-153 (2014).
24. Brown, J. E. et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl Cancer Inst. 97, 59-69 (2005).
25. Lipton, A. et al. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses. Clin. Oncol. (R. Coll. Radiol.) 25, 217-226 (2013).
26. Smith, M. R. et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 70, 315-319 (2007).
27. de la Piedra, C. et al. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study. Br. J. Cancer 108, 2565-2572 (2013).
28. Lipton, A. et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113, 193-201 (2008).
29. Stoch, S. A. et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J. Clin. Endocrinol. Metab. 86, 2787-2791 (2001).
30. Lee, H., McGovern, K., Finkelstein, J. S. & Smith, M. R. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104, 1633-1637 (2005).
31. Diamond, T. H., Higano, C. S., Smith, M. R., Guise, T. A. & Singer, F. R. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 100, 892-899 (2004).
32. Shahinian, V. B., Kuo, Y. F., Freeman, J. L. & Goodwin, J. S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 352, 154-164 (2005).
33. Smith, M. R. et al. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J. Clin. Oncol. 23, 7897-7903 (2005).
34. López, A. M. et al. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos. Int. 16, 707-711 (2005).
35. Beebe-Dimmer, J. L. et al. Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States. Pharmacoepidemiol. Drug Saf. 21, 70-78 (2012).
36. LeBlanc, E. S. et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J. Clin. Endocrinol. Metab. 94, 3337-3346 (2009).
37. Novara, G., Galfano, A., Secco, S., Ficarra, V. & Artibani, W. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urol. Int. 82, 249-255 (2009).
38. Vidal, O., Kindblom, L. G. & Ohlsson, C. Expression and localization of estrogen receptor-beta in murine and human bone. J. Bone Miner. Res. 14, 923-929 (1999).
39. [No authors listed] Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17, 25-54 (2010).
40. Smith, M. R., Fallon, M. A., Lee, H. & Finkelstein, J. S. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89, 3841-3846 (2004).
41. Smith, M. R. et al. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 189 (Suppl. 1), S45-S50 (2013).
42. Lin, J. H. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18, 75-85 (1996).
43. Saad, F. et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94, 1458-1468 (2002).
44. Rosen, L. S. et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7, 377-387 (2001).
45. Neville-Webbe, H. L. & Coleman, R. E. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur. J. Cancer 46, 1211-1222 (2010).
46. Michaelson, M. D. et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J. Clin. Oncol. 25, 1038-1042 (2007).
47. Kachnic, L. A. et al. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer Prostatic Dis. 16, 382-386 (2013).
48. Wadhwa, V. K., Weston, R. & Parr, N. J. Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU Int. 105, 1082-1088 (2010).
49. Smith, M. R. et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J. Urol. 169, 2008-2012 (2003).
50. Klotz, L. H. et al. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Eur. Urol. 63, 927-935 (2013).
51. Greenspan, S. L. et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J. Clin. Oncol. 26, 4426-4434 (2008).
52. Smith, M. R. et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 345, 948-955 (2001).
53. Morabito, N. et al. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J. Bone Miner. Res. 19, 1766-1770 (2004).
54. Dearnaley, D. P., Mason, M. D., Parmar, M. K., Sanders, K. & Sydes, M. R. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 10, 872-876 (2009).
55. Mason, M. D. et al. Oral sodium clodronate for nonmetastatic prostate cancer-results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J. Natl Cancer Inst. 99, 765-776 (2007).
56. Dearnaley, D. P. et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst. 95, 1300-1311 (2003).
57. Small, E. J., Smith, M. R., Seaman, J. J., Petrone, S. & Kowalski, M. O. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J. Clin. Oncol. 21, 4277-4284 (2003).
58. Smith, M. R. et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J. Clin. Oncol. 23, 2918-2925 (2005).
59. Wirth, M. et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). Eur. Urol. http://dx.doi.org/10. 1016/j.eururo.2014.02.014 (2014).
60. Smith, M. R. et al. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J. Urol. 182, 2670-2675 (2009).
61. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00925600 (2013).
62. US Food and Drug Administration. Denosumab (prolia) [online], http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ucm272420.htm (2011).
63. Jones, D. H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440, 692-696 (2006).
64. Smith, M. R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379, 39-46 (2012).
65. Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J. Clin. Oncol. 30, 3800-3806 (2013).
66. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
67. US Food and Drug Administration. Denosumab [online], http://www.fda.gov/ aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm248277.htm (2010).
68. Robinson, R. G. et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 9, 271-281 (1989).
69. Bauman, G., Charette, M., Reid, R. & Sathya, J. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. Radiother. Oncol. 75, 258-270 (2005).
70. Henriksen, G., Fisher, D. R., Roeske, J. C., Bruland, O. S. & Larsen, R. H. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J. Nucl. Med. 44, 252-259 (2003).
71. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
72. Tu, S. M. et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357, 336-341 (2001).
73. James, N. D. et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747) [abstract]. J. Clin. Oncol. 31 (Suppl.), LBA5000 (2013).
74. Bruland, O. S., Nilsson, S., Fisher, D. R. & Larsen, R. H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin. Cancer Res. 12, 6250s-6257s (2006).
75. Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
76. US Food and Drug Administration. Radium Ra 223 dichloride [online], http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm352393.htm (2013).
77. Nelson, J. B. et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1, 944-949 (1995).
78. Yin, J. J. et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl Acad. Sci. USA 100, 10954-10959 (2003).
79. Saad, F. & Lipton, A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat. Rev. 36, 177-184 (2010).
80. Tatarov, O. et al. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 15, 3540-3549 (2009).
81. Nelson, J. B. et al. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 118, 5709-5718 (2012).
82. Fizazi, K. S. et al. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 31, 1740-1747 (2013).
83. Nelson, J. B. et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 113, 2478-2487 (2008).
84. Quinn, D. I. et al. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 14, 893-900 (2013).
85. Araujo, J. C. et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol. 14, 1307-1316 (2013).
86. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
87. Logothetis, C. J. et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13, 1210-1217 (2012).
88. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
89. Saad, F. et al. Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P) [abstract]. J. Clin. Oncol. 31 (Suppl.), a5037 (2013).
90. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
91. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT02003924 (2013).
92. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01946204 (2014).
93. Smith, D. C. et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol. 31, 412-419 (2013).
94. Dai, J. et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin. Cancer Res. 20, 617-630 (2014).
95. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01703065 (2013).
96. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01599793 (2014).
97. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01605227 (2014).
98. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01522443 (2014).
99. Epstein, J. et al. Postradiation osteonecrosis of the mandible: a long-term follow-up study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 83, 657-662 (1997).
100. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws & American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 65, 369-376 (2007).
101. Pazianas, M., Miller, P., Blumentals, W. A., Bernal, M. & Kothawala, P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin. Ther. 29, 1548-1558 (2007).
102. Bamias, A. et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol. 23, 8580-8587 (2005).
103. Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341-1347 (2012).
104. Badros, A. et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J. Clin. Oncol. 24, 945-952 (2006).
105. Ripamonti, C. I. et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20, 137-145 (2009).
106. Dimopoulos, M. A. et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20, 117-120 (2009).
107. Perazella, M. A. & Markowitz, G. S. Bisphosphonate nephrotoxicity. Kidney Int. 74, 1385-1393 (2008).
108. Chang, J. T., Green, L. & Beitz, J. Renal failure with the use of zoledronic acid. N. Engl. J. Med. 349, 1676-1679 (2003).
109. Block, G. A., Bone, H. G., Fang, L., Lee, E. & Padhi, D. A single-dose study of denosumab in patients with various degrees of renal impairment. J. Bone Miner. Res. 27, 1471-1479 (2012).